Borea Therapeutics

Executive Summary

Borea Therapeutics is an Italian biotechnology company founded in 2020 and headquartered in Milan, focused on developing novel gene therapies for genetic and chronic diseases. The company's core innovation lies in its universal gene therapy platform, which leverages proprietary viral vectors to achieve safe and targeted gene transfer. By engineering vectors with enhanced tropism and reduced immunogenicity, Borea aims to overcome key limitations of current gene therapy approaches, such as off-target effects and limited payload capacity. The platform is designed to be modular, enabling rapid adaptation to different disease indications. Borea's initial focus areas include rare genetic disorders with high unmet medical need, where a single-dose gene therapy could provide durable therapeutic benefit. The company operates in the competitive gene therapy landscape but differentiates itself through its vector engineering expertise and focus on underserved patient populations.

Upcoming Catalysts (preview)

• Q2 2027IND Filing for Lead Gene Therapy Candidate40% success
• Q4 2027Initiation of First-in-Human Phase 1 Trial30% success
• Q3 2026Publication of Preclinical Proof-of-Concept Data in Peer-Reviewed Journal70% success